Clinical trial
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter…
NCT00126022 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00126022 |
|---|---|
| Title | Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects |
| Official title | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Atrial Flutter |
| Intervention type | Drug |
| Interventions | Tedisamil sesquifumarate |
| Start date | Dec 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Aug 2, 2005 |
| Last update posted | Jan 16, 2015 |
| Countries | Argentina, Czechia, Germany, Israel, Poland, Romania, Russia, Serbia and Montenegro, Slovakia, South Africa, Ukraine, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: